Would you offer neoadjuvant chemotherapy prior to trimodality therapy in a fit patient who refuses surgery for muscle-invasive bladder cancer?
Micrometastatic disease clearance is essential to prevent late relapse. This approach is often undertaken at centers in Ontario and the UK, though little data exists, unfortunately, due to TMT previously being used for older, cis-ineligible patients. Would ctDNA sway your decision?
1 Answer
Mednet Member
Medical Oncology · Mayo Clinic
Answered on
Unfortunately, this is a question without a clear answer at this time. Trimodality therapy, consisting of maximal TURBT, chemotherapy, and radiation, appears to have equivalent outcomes and has NCCN Category 1 recommendations for patients with MIBC. We do not routinely do neoadjuvant chemotherapy fo...
Join for free or sign in to see the full answer